Seretide is indicated in the regular treatment of asthma where use of a combination product (long- acting β2 agonist and inhaled corticosteroid) is appropriate:
The recommended dose of Seretide Evohaler 25/50mcg, 25/125mcg or 25/250mcg is two inhalations, twice daily.
Seretide Evohaler comes in three different doses allowing flexibility of dosing for your patient with asthma at low, medium and high dose inhaled steroid1.
75% of patients given Seretide achieved control and were still well controlled after 1 year.2 Patients should not need their rescue inhaler 6 days out of 7 (extrapolated from the GOAL study data)*3
Allowing patients to step up and
down as needed; providing
continuity of care and an individual
approach to managing asthma control1
Seretide 25/50 mcg Evohaler is the only MDI licensed in paediatric asthma for children 4 years and upwards, which can be used with both the Volumatic and Aerochamber1
*GOAL Study Stratum 2 patients defined as those patients who were on 500 µg or less of beclomethasone propionate daily or equivalent. The GOAL data has been extrapolated from over one year into one week4.
Seretide 25/50 mcg Evohaler is the only MDI licensed in paediatric asthma for children 4 years and upwards, which can be used with both the Volumatic and Aerochamber1.
Compared to Fostair5...
Compared to Sirdupla8, Seretide...
Provides a numerical score that helps healthcare professionals and their patients determine if asthma symptoms are well controlled.Order now
This Placebo Demonstration Device helps healthcare professionals show patients how to use the Evohaler device correctly.Order now
How to Use Patient Leaflet Pad to support patients to correctly use their Evohaler on its own and with a Volumatic Spacer.Order now
For Commissioners and Payers
To review the estimated financial savings of the 2018 Seretide list price change for your LHE, please visit value.gsk.com
If you have an active Seretide Rebate contract please log into our value.gsk.com site for more information about what the 2018 Seretide price changes mean to your LHE.
If you are not registered, and you are a NHS medicine manager, respiratory commissioner or in an equivalent role, you can register quickly and easily by visiting value.gsk.com
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
Seretide is a registered trademark of the GlaxoSmithKline group of companies
A.K Last Updated September 2019 PM-GB-FPS-WCNT-190006